Stocksigma LogoStocksigma Logo

Windlas Biotech Q2 Results and Board Leadership Restructuring

Windlas Biotech reported Q2'27 revenue from operations of ₹2,639.08m, up 18.7% YoY and 6.4% QoQ, while net profit stood at ₹180.52m compared to ₹178.00m in

Windlas Biotech Q2 Results and Board Leadership Restructuring

Windlas Biotech Ltd · Change in Management · 05 Nov 2026, 10:48 pm

Windlas Biotech Q2 Results and Board Leadership Restructuring Windlas Biotech reported Q2'27 revenue from operations of ₹2,639.08m, up 18.7% YoY and 6.4% QoQ, while net profit stood at ₹180.52m compared to ₹178.00m in Q2'26. For H1'27, revenue reached ₹5,120.07m with net profit at ₹357.05m. The Board approved the succession plan wherein Mr. Ashok Kumar Windlass resigned as Whole-time Director effective 5th Nov'26, transitioning to Founder President (SMP) from 6th Nov'26. Additionally, MD Mr. Hitesh Windlass was appointed as Chairman of the Board effective 5th Nov'26.

Original exchange filing (PDF)

More announcements from Windlas Biotech Ltd

All Windlas Biotech Ltd announcements